Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
27 hedge funds and large institutions have $6.45M invested in Evoke Pharma in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
29% more funds holding
Funds holding: 21 → 27 (+6)
0.03% more ownership
Funds ownership: 0.09% → 0.13% (+0.03%)
8% less capital invested
Capital invested by funds: $7.02M → $6.45M (-$575K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$576K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$570K |
| 3 |
6CM
683 Capital Management
New York
|
+$329K |
| 4 |
BRF
B. Riley Financial
Los Angeles,
California
|
+$317K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$288K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$183K |
| 2 |
VF
Virtu Financial
New York
|
-$51.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$46K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$37K |
| 5 |
FM
Family Management
New York
|
-$35K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| $1K | – | – | – |
|
|
27
Millennium Management
New York
| – | -$183K | -381 | Closed |
|
|
TSS
28
Two Sigma Securities
New York
| – | -$37K | -77 | Closed |
|
|
FM
29
Family Management
New York
| – | -$35K | -72 | Closed |
|
30
Bank of America
Charlotte,
North Carolina
| – | -$33K | -69 | Closed |
|
|
CHP
31
Cable Hill Partners
Portland,
Oregon
| – | +$415 | +1 | New |
|
EVOK Hedge Fund Activity: Q4 2017 in Review
27 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2017, worth a combined $6.45M — down 8.2% from $7.02M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new EVOK positions and 4 closed out — a net gain of 6 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $576K. The largest seller was Millennium Management, exiting entirely with an estimated $183K sold.
- 27 institutional investors held Evoke Pharma (EVOK) as of Q4 2017, up from 21 in Q3 2017.
- Funds reported $6.45M of Evoke Pharma stock for Q4 2017, down 8.2% quarter-over-quarter.
- 10 funds opened new Evoke Pharma positions in Q4 2017 and 4 closed out, a net change of +6 holders.
- The largest Evoke Pharma buyer in Q4 2017 was Deutsche Bank, an estimated $576K added.
- The largest Evoke Pharma seller in Q4 2017 was Millennium Management, an estimated $183K sold.
Based on aggregated 13F filings for Q4 2017.